Facetten
Zugriff
Einrichtung
Medientyp
- Text 7
Karte
Erscheinungsjahr
Autor/in
- Gooderham, Melinda
- Reich, Kristian 6
- Griffiths, Christopher E M 2
- Paul, Carle 2
- Thaçi, Diamant 2
- alle zeigen
Sprache
- Englisch 7
7 Einträge gefunden
-
-
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial
- Reich, Kristian
- Kristensen, Lars Erik
- Smith, Saxon D
- Rich, Phoebe
- Sapin, Christophe
- Leage, Soyi Liu
- McKenzie, Robert
-
Bimekizumab versus Secukinumab in Plaque Psoriasis
- Reich, Kristian
- Warren, Richard B
- Lebwohl, Mark
- Gooderham, Melinda
- Strober, Bruce
- Langley, Richard G
- Paul, Carle
-
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
- Armstrong, April
- Paul, Carle
- Puig, Luis
- Boehncke, Wolf Henning
- Freeman, Michael
- Torii, Hideshi
- Papp, Kim
-
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
- Leonardi, Craig
- Reich, Kristian
- Foley, Peter
- Torii, Hideshi
- Gerdes, Sascha
- Guenther, Lyn
- Gooderham, Melinda
-
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
- Reich, Kristian
- Gooderham, Melinda
- Thaçi, Diamant
- Crowley, Jeffrey J
- Ryan, Caitriona
- Krueger, James G
- Tsai, Tsen-Fang
-
Tofacitinib Improves Pruritus and Health-Related Quality of Life up to 52 weeks: Results from 2 Randomized Phase III Trials in Patients With Moderate to Severe Plaque Psoriasis
- Feldman, Steven R
- Thaçi, Diamant
- Gooderham, Melinda
- Augustin, Matthias
- de la Cruz, Claudia
- Mallbris, Lotus
- Buonanno, Marjorie